BioCardia (NASDAQ:BCDA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $25.00 price target on the stock.

BioCardia Stock Down 8.2 %

Shares of BCDA stock opened at $1.85 on Thursday. BioCardia has a 12-month low of $1.84 and a 12-month high of $14.40. The firm has a fifty day moving average of $2.58 and a 200-day moving average of $3.30. The company has a market capitalization of $3.92 million, a price-to-earnings ratio of -0.44 and a beta of 1.28.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.